EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A pharmacokinetic–pharmacodynamic analysis of l ‐glutamine for the treatment of sickle cell disease: Implications for understanding the mechanism of action and evaluating response to therapy

Alina Sadaf, Min Dong, Amanda Pfeiffer, Jennifer Korpik, Theodosia A Kalfa, Teresa Latham, Alexander A Vinks, Russell E Ware iD, Charles T Quinn iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Alina Sadaf und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Glutamine, Anemia, Sickle Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mechanisms of action of l ‐glutamine for the treatment of sickle cell disease (SCD) are not well understood and there are no validated clinical biomarkers to assess response. We conducted a three‐week, dose‐ascending trial of glutamine and measured the pharmacokinetic (PK) exposure parameters, peak concentration ( C max ) and area under the curve (AUC). We used a panel of biomarkers to investigate the pharmacodynamics (PD) of glutamine and studied PK–PD relationships. There was no plasma accumulation of glutamine, glutamate, arginine or other amino acids over time, but modestly improved arginine bioavailability was observed. In standard analysis by dose levels over time, there were no measurable effects on blood counts, viscosity, ektacytometry or reactive oxygen species (ROS). In PK–PD analysis, however, higher glutamine exposure ( C max or AUC) was associated with increased whole blood viscosity and cellular dehydration, yet also with higher haemoglobin concentration, increased haematocrit‐to‐viscosity ratio, decreased reticulocyte ROS, improved RBC deformability and decreased point of sickling. This novel PK–PD analysis identified biomarkers reflecting the positive and negative effects of glutamine, helping to elucidate its mechanisms of action in SCD. PK‐optimized dosing to achieve glutamine exposure (AUC or C max ) that is associated with salutary biological effects should be studied to support its therapeutic use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutamineAnemia, Sickle CellHumansMaleAdultFemaleReactive Oxygen SpeciesBiomarkersYoung AdultBlood Viscosity

Stichwörter der Autor:innen

biomarkersl‐glutaminepharmacodynamicspharmacokineticssickle cell disease

Substanzen

GlutamineReactive Oxygen SpeciesBiomarkers

Autor:innen und Institutionen

  • Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Erythrocyte Diagnostic Laboratory, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

ORCID-Profile: Russell E Ware, Charles T Quinn

Zitieren

APA

Sadaf, A., Dong, M., Pfeiffer, A., Korpik, J., Kalfa, T. A., Latham, T., Vinks, A. A., Ware, R. E., & Quinn, C. T. (2024). A pharmacokinetic–pharmacodynamic analysis of l ‐glutamine for the treatment of sickle cell disease: Implications for understanding the mechanism of action and evaluating response to therapy. British Journal of Haematology. https://doi.org/10.1111/bjh.19632

Vancouver

Sadaf A, Dong M, Pfeiffer A, Korpik J, Kalfa TA, Latham T, et al. A pharmacokinetic–pharmacodynamic analysis of l ‐glutamine for the treatment of sickle cell disease: Implications for understanding the mechanism of action and evaluating response to therapy. British Journal of Haematology. 2024. doi:10.1111/bjh.19632

BibTeX
@article{Sadaf2024,
  author = {Sadaf, Alina and Dong, Min and Pfeiffer, Amanda and Korpik, Jennifer and Kalfa, Theodosia A and Latham, Teresa and Vinks, Alexander A and Ware, Russell E and Quinn, Charles T},
  title = {A pharmacokinetic–pharmacodynamic analysis of l ‐glutamine for the treatment of sickle cell disease: Implications for understanding the mechanism of action and evaluating response to therapy},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19632}
}
Kostenlos starten →